Based on their ability to reduce hyperglycemia and body weight, the U.S. food and drug administration (FDA) approved the use of Glucagon-like peptide-1 receptor (GLP-1R) agonists as a treatment for type-2 patients (100). This evidence concerns the gene GLP1R and Hyperglycemia.